共 179 条
[1]
Bonadonna G(1976)Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405-410
[2]
Brusamolino E(2014)Characterization of PTPN2 and its use as a biomarker Methods 65 239-246
[3]
Valagussa P(1991)Activation of transcription via AP-1 or CREB regulatory sites is blocked by protein tyrosine phosphatases Oncogene 6 1203-1209
[4]
Rossi A(1989)cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family Proc Natl Acad Sci USA 86 5257-5261
[5]
Brugnatelli L(2011)Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1747
[6]
Brambilla C(2008)Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 1995-2004
[7]
De Lena M(2015)Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer Breast Cancer Res Treat 153 31-40
[8]
Tancini G(2018)PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer J Cancer Res Clin Oncol 145 599-535
[9]
Bajetta E(2010)Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia Nat Genet 42 530-1727
[10]
Musumeci R(2011)Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma Haematologica 96 1723-37707